Abstract
Apatinib, an antiangiogenic drug, has shown beneficial effects only in a fraction of advanced gastric cancer (GC) patients. Given the recent success of immunotherapies, combination of apatinib with immune checkpoint inhibitor may provide sustained and potent antitumor responses. Immunocompetent mice with subcutaneous MFC tumors grown were given a combination of apatinib and anti-PD-L1 antibody therapy. GC tissues from patients undergoing curative resection in China were collected, and the density of HEVs, MSI status and tumor-infiltrated lymphocytes were analyzed by immunohistochemical staining. Combined apatinib and PD-L1 blockade therapy synergistically delayed tumor growth and increased survival in MFC-bearing immunocompetent mice. The combination therapy promoted antitumor immunity by increasing the ratio of CD8+ cytotoxic T cells to Foxp3+ Treg cells, the accumulation of CD20+ B cells and the Th1/Th2 cytokine ratio (IFN-γ/IL-10). The combination therapy induced the formation of HEVs through activation of LTβR signaling, thus promoting CD8+ cytotoxic T cell and CD20+ B cell infiltration in tumors. In clinical GC samples, the density of HEVs positively correlated with the intratumoral infiltration of CD8+ cytotoxic T cells and CD20+ B cells. MSI-high GC showed a higher density of HEVs, CD8+ cytotoxic T cells and CD20+ B cells than MSS/MSI-low GC. GC patients with high densities of HEVs, CD8+ cytotoxic T cells and CD20+ B cells had an improved prognosis with superior overall survival. Combining apatinib with PD-L1 blockade treatment synergistically enhances antitumor immune responses and promotes HEV formation in GC.
Highlights
Apatinib, an antiangiogenic drug, has showed beneficial effects only in a fraction of advanced gastric cancer (GC) patients
To investigate whether combined therapy would be more efficacious than apatinib or programmed death ligand 1 (PD-L1) blockade monotherapy, we performed a therapeutic study in a cell line-derived xenograft (CDX) murine model
After 2 weeks of treatment, we found that treatment with apatinib or anti-PDL1 antibody alone significantly inhibited the growth of MFC tumors in immunocompetent mice, and combination treatment with apatinib and anti-PD-L1 antibody led to a further reduction in tumor volume and tumor weight (Fig. 1d-e)
Summary
An antiangiogenic drug, has showed beneficial effects only in a fraction of advanced gastric cancer (GC) patients. Given the recent success of immunotherapies, combination of apatinib with immune checkpoint inhibitor may provide sustained and potent antitumor responses. Tumor angiogenesis supplies nutrients and oxygen to cancer tissues and actively modulates antitumor immune activity[3]. A functional inhibitor of VEGF/VEGFR-2, has recently been approved and indicated for advanced gastric cancer after the failure of two or more lines of systemic therapy in China[7]. On this basis, inhibiting VEGF/VEGFR-2 signaling with apatinib may induce a transient state of vessel remodeling to facilitate lymphocyte infiltration in tumor tissues
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
